Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.

Published

Journal Article

BACKGROUND:The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) study assessed the efficacy of cetuximab monotherapy compared with cetuximab combined with chemotherapy for quadruple wild-type (KRAS, NRAS, BRAF, or P13KCA exon 20) metastatic colorectal cancer. PATIENTS AND METHODS:Patients were enrolled in an open-label, multicenter, phase II trial and randomly assigned to cetuximab 400 mg/m2, then 250 mg/m2 cetuximab weekly, with or without irinotecan 180 mg/m2 every 2 weeks. The primary endpoint was 6-month progression-free survival; secondary endpoints were response rate, overall survival, toxicity, and quality of life. RESULTS:From 2012 to 2016, 48 patients were recruited. Two were ineligible, and 2 were not evaluable for response. Characteristics were balanced, except gender (male, 62% vs. 72%) and primary sidedness (left, 95% vs. 68%). For cetuximab compared with cetuximab-irinotecan, progression-free survival was 14% versus 41% (hazard ratio, 0.39; 95% confidence interval, 0.20-0.78; P = .008); response rate was 10% (2 partial responses) versus 38% (1 complete, 8 partial); P = .04. Grade 3 to 4 toxicities were less with cetuximab monotherapy (23% vs. 50%); global and specific quality of life scores did not differ. CONCLUSION:In comparison with cetuximab alone, cetuximab plus irinotecan increases the response rate and delays progression in irinotecan-resistant RAS wild-type colorectal cancer. This echoes data from molecularly unselected patients.

Full Text

Duke Authors

Cited Authors

  • Shapiro, JD; Thavaneswaran, S; Underhill, CR; Robledo, KP; Karapetis, CS; Day, FL; Nott, LM; Jefford, M; Chantrill, LA; Pavlakis, N; Tebbutt, NC; Price, TJ; Khasraw, M; Van Hazel, GA; Waring, PM; Tejpar, S; Simes, J; Gebski, VJ; Desai, J; Segelov, E

Published Date

  • December 2018

Published In

Volume / Issue

  • 17 / 4

Start / End Page

  • 313 - 319

PubMed ID

  • 30463680

Pubmed Central ID

  • 30463680

Electronic International Standard Serial Number (EISSN)

  • 1938-0674

International Standard Serial Number (ISSN)

  • 1533-0028

Digital Object Identifier (DOI)

  • 10.1016/j.clcc.2018.06.002

Language

  • eng